Immunology Company Kira Biotech launches with A$20M Series A Funding

Brisbane, 29 October 2019: Kira Biotech today announced it has secured Series A funding of A$20 million to develop therapeutics targeting difficult-to-treat immune system disorders.

The round was led by OneVentures, with significant investment from IP Group and support from the Advance Queensland Business Development Fund. The funds will help advance Kira Biotech’s lead candidate KB312 through phase 1 human studies.  Read More


We're not around right now. But you can send us an email and we'll get back to you, asap.


©2023 Dendritic Cell Research

Log in with your credentials

Forgot your details?